{"id":619003,"date":"2026-10-19T08:54:29","date_gmt":"2026-10-19T08:54:29","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/619003\/celiac-disease-market-analysis-2034-industry-trends-market-size-and-emerging-therapeutic-developments-delveinsight-zedira-dr-falk-pharma-takeda-immunogenx-provention-bio-sanofi.html"},"modified":"2026-10-19T08:54:29","modified_gmt":"2026-10-19T08:54:29","slug":"celiac-disease-market-analysis-2034-industry-trends-market-size-and-emerging-therapeutic-developments-delveinsight-zedira-dr-falk-pharma-takeda-immunogenx-provention-bio-sanofi","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/619003\/celiac-disease-market-analysis-2034-industry-trends-market-size-and-emerging-therapeutic-developments-delveinsight-zedira-dr-falk-pharma-takeda-immunogenx-provention-bio-sanofi.html","title":{"rendered":"Celiac Disease Market Analysis 2034: Industry Trends, Market Size, and Emerging Therapeutic Developments \u2013 DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1792179847.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Celiac Disease Market Analysis 2034: Industry Trends, Market Size, and Emerging Therapeutic Developments &ndash; DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1792179847.jpg\" alt=\"Celiac Disease Market Analysis 2034: Industry Trends, Market Size, and Emerging Therapeutic Developments &ndash; DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi\" width=\"225\" height=\"95\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The Key Celiac Disease Companies in the market include &#8211; Takeda, AnokionSA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others.<\/div>\n<p style=\"text-align: justify\"><strong>(Albany, New York) &#8211; October 19, 2026:<\/strong> DelveInsight&rsquo;s<strong> &ldquo;Celiac Disease Market Insights, Epidemiology, and Market Forecast-2034&Prime;<\/strong> report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>To Know in detail about the Celiac Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/celiac-disease-cd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Celiac Disease Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Some of the key facts of the Celiac Disease Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The Celiac Disease market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period (2020-2034).<\/p>\n<\/li>\n<li>\n<p><strong>In October 2026,<\/strong> the company reported positive top-line results from a Phase 1b gluten-challenge cohort. ANB033 demonstrated a statistically significant protective effect on intestinal histology and reduced gluten-induced symptoms versus placebo. The treatment targets immune pathways involving IL-15 and IL-2. These are early-stage findings and require further clinical evaluation.<\/p>\n<\/li>\n<li>\n<p><strong>In October 2026, argenx<\/strong> announced positive Phase 2 results for FB102, a CD122 inhibitor acquired from Forte Biosciences. The trial met its primary endpoint, showing a statistically significant improvement in the villus-height-to-crypt-depth ratio versus placebo following gluten challenge ((p=0.0176)). The company plans to advance FB102 into Phase 3 development.<\/p>\n<\/li>\n<li>\n<p><strong>In September 2026, Teva<\/strong> reported positive top-line results from a Phase 2a trial of its investigational anti-IL-15 monoclonal antibody. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful protection against gluten-induced intestinal damage versus placebo at Week 8. No safety signals were reported at the time of the announcement.<\/p>\n<\/li>\n<li>\n<p><strong>In September 2026, Novartis<\/strong> paused its autoimmune CAR-T clinical trials following three reported deaths. Meanwhile, this week&rsquo;s major developments included the first gene therapy for Huntington&rsquo;s disease being submitted to the FDA, an mRNA-based influenza vaccine progressing to Phase 3 trials, promising developments in an antibody therapy for celiac disease, and several other key updates.<\/p>\n<\/li>\n<li>\n<p><strong>In July 2026, <\/strong>Argenx has entered into a definitive agreement to acquire Forte Biosciences in an all-cash transaction valued at approximately $2.2 billion. The acquisition strengthens argenx&#8217;s immunology pipeline by adding a first-in-class anti-CD122 monoclonal antibody that has shown early clinical promise in vitiligo and celiac disease. The clinical-stage therapy targets a key signaling pathway involving T cells and natural killer (NK) cells, expanding argenx&#8217;s portfolio of innovative immune-mediated disease treatments.<\/p>\n<\/li>\n<li>\n<p><strong>In February 2026, Forte Biosciences<\/strong> initiated enrollment in the Phase II FB102-301 trial, evaluating FB102 in adults with celiac disease who continue to experience symptoms despite adhering to a gluten-free diet. The study is designed to assess the safety and efficacy of FB102 as a potential disease-modifying therapy<\/p>\n<\/li>\n<li>\n<p><strong>In June 2025, Forte Biosciences, Inc. (NASDAQ: FBRX)<\/strong>, a clinical-stage biopharmaceutical company specializing in autoimmune and related disorders, has reported positive results from a Phase 1b trial of its lead candidate, FB102 (study FB102-101), in celiac disease.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2025, Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA)<\/strong> announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug TEV-53408, an anti-IL-15 antibody, for the treatment of celiac disease in patients adhering to a gluten-free diet. TEV-53408 is currently undergoing evaluation in a Phase 2a clinical trial to determine its safety and effectiveness in adults with celiac disease. The FDA&#8217;s Fast Track program aims to speed up the development and review of therapies for serious conditions with significant unmet medical needs.<\/p>\n<\/li>\n<li>\n<p><strong>In February 2025, Phase V,<\/strong> a leader in software and machine learning (ML) solutions for clinical trial optimization, announced a strategic partnership with Alimentiv Inc., a global gastrointestinal (GI) contract research organization (CRO). This collaboration aims to enhance the design and execution of advanced adaptive clinical trials targeting various GI disorders, including inflammatory bowel disease (IBD), celiac disease, and eosinophilic gastrointestinal disease (EGID). By applying adaptive trial methodologies, the partnership seeks to boost trial efficiency and improve patient outcomes, ultimately accelerating the development of innovative therapies for individuals suffering from these complex GI conditions.<\/p>\n<\/li>\n<li>\n<p>In 2023, the United States represented the largest portion of the celiac disease market among the 7MM, contributing roughly 70% to the overall market.<\/p>\n<\/li>\n<li>\n<p>Among the EU4 and the UK, Italy had the highest market valuation for celiac disease, estimated at around <strong>USD 200 million.<\/strong><\/p>\n<\/li>\n<li>\n<p>At present, a gluten-free diet is the sole effective treatment for celiac disease, with the market in Japan valued at around <strong>USD 1,500 million in 2023<\/strong>.<\/p>\n<\/li>\n<li>\n<p>Celiac disease exhibits a significant gender imbalance, primarily affecting females. In Germany, for example, around 60% of diagnosed cases are female.<\/p>\n<\/li>\n<li>\n<p>In 2023, classical celiac disease accounted for approximately 30% of all celiac disease cases in Japan.<\/p>\n<\/li>\n<li>\n<p>According to the Beyond Celiac foundation (2024), approximately 1 in 133 Americans, or around 1% of the population, has celiac disease. It is also estimated that up to 83% of Americans with celiac disease remain undiagnosed or are incorrectly diagnosed with other medical conditions.<\/p>\n<\/li>\n<li>\n<p>According to Stahl et al. (2023), Celiac disease is a prevalent chronic condition globally, with an aggregated prevalence of 1.4%, though it can be significantly higher in specific regions. In a prospective birth cohort study involving infants at risk for celiac disease in Europe and the United States, the incidence was estimated to be 3% in Sweden and 2.4% in Colorado.<\/p>\n<\/li>\n<li>\n<p>According to the Celiac Disease Foundation, celiac disease is a significant autoimmune disorder estimated to impact 1 in 100 people globally. Additionally, 2.5 million Americans remain undiagnosed and are susceptible to potential long-term health issues.<\/p>\n<\/li>\n<li>\n<p><strong>Key Celiac Disease Companies:<\/strong> Takeda, AnokionSA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Celiac Disease Therapies:<\/strong> TAK-062, KAN-101, MTX 101, AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others<\/p>\n<\/li>\n<li>\n<p>The Celiac Disease epidemiology based on gender analyzed that, females are affected more than males<\/p>\n<\/li>\n<li>\n<p>The Celiac Disease market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Celiac Disease pipeline products will significantly revolutionize the Celiac Disease market dynamics.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Celiac Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify\">Celiac disease is a chronic autoimmune disorder triggered by the ingestion of gluten, a protein found in wheat, barley, and rye. When individuals with celiac disease consume gluten, their immune system responds by damaging the lining of the small intestine, leading to malabsorption of nutrients and a range of symptoms.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Get a Free sample for the Celiac Disease Market Report: <\/strong><\/p>\n<p style=\"text-align: justify\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/celiac-disease-cd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">https:\/\/www.delveinsight.com\/report-store\/celiac-disease-cd-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Celiac Disease Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Celiac Disease Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify\">The Celiac Disease market report proffers epidemiological analysis for the study period 2020&ndash;2034 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Prevalent Population of Celiac Disease in the 7MM<\/p>\n<\/li>\n<li>\n<p>Total Diagnosed Prevalent Population of Celiac Disease in the 7MM<\/p>\n<\/li>\n<li>\n<p>Type-specific Prevalent Population of Celiac Disease in the 7MM<\/p>\n<\/li>\n<li>\n<p>Gender-specific Prevalent Population of Celiac Disease in the 7MM<\/p>\n<\/li>\n<li>\n<p>Age-specific Distribution of Celiac Disease in the 7MM<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Download the report to understand which factors are driving Celiac Disease epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/celiac-disease-cd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Celiac Disease Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Celiac Disease Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Celiac Disease market or expected to get launched during the study period. The analysis covers Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify\">The report also covers the Celiac Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Celiac Disease Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>TAK-062: Takeda<\/p>\n<\/li>\n<li>\n<p>KAN-101: AnokionSA<\/p>\n<\/li>\n<li>\n<p>MTX 101: Mozart Therapeutics<\/p>\n<\/li>\n<li>\n<p>AMY02: AMYRA Biotech AG<\/p>\n<\/li>\n<li>\n<p>EQ102: Equillium Bio.<\/p>\n<\/li>\n<li>\n<p>DONQ52: Chugai Pharmaceutical Co., Ltd.<\/p>\n<\/li>\n<li>\n<p>CALY-002: Calypso Biotech<\/p>\n<\/li>\n<li>\n<p>Latiglutenase : ImmunogenX, Inc.<\/p>\n<\/li>\n<li>\n<p>Ordesekimab: Amgen Inc.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Discover more about therapies set to grab major Celiac Disease market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/celiac-disease-cd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Celiac Disease Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Celiac Disease Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Rising prevalence of celiac disease worldwide, supported by improved awareness and increased screening, is expanding the diagnosed patient population.<\/p>\n<\/li>\n<li>\n<p>Growing adoption of serological and genetic testing is enabling earlier and more accurate diagnosis, driving treatment demand.<\/p>\n<\/li>\n<li>\n<p>Increasing awareness among healthcare professionals and patients is reducing underdiagnosis and encouraging timely disease management.<\/p>\n<\/li>\n<li>\n<p>Robust pipeline of novel therapeutics, including gluten-degrading enzymes, immune-modulating therapies, and tight junction regulators, is expected to transform the treatment landscape beyond a gluten-free diet.<\/p>\n<\/li>\n<li>\n<p>Limitations of a strict gluten-free diet (GFD), including compliance challenges and accidental gluten exposure, are creating demand for adjunctive and alternative therapies.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Celiac Disease Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>The gluten-free diet remains the standard of care, reducing the immediate need for pharmacological therapies in many patients.<\/p>\n<\/li>\n<li>\n<p>High rates of undiagnosed or misdiagnosed cases continue to limit the addressable treatment population.<\/p>\n<\/li>\n<li>\n<p>Complex disease pathophysiology and the lack of validated surrogate endpoints make drug development challenging.<\/p>\n<\/li>\n<li>\n<p>Clinical trial recruitment difficulties, driven by strict eligibility criteria and dietary adherence requirements, can delay product development.<\/p>\n<\/li>\n<li>\n<p>Potential safety concerns associated with long-term immune-modulating therapies may affect regulatory approval and physician acceptance.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Scope of the Celiac Disease Market Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>Study Period: 2020&ndash;2034<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Celiac Disease Companies:<\/strong> Takeda, AnokionSA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Celiac Disease Therapies:<\/strong> TAK-062, KAN-101, MTX 101, AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others<\/p>\n<\/li>\n<li>\n<p><strong>Celiac Disease Therapeutic Assessment:<\/strong> Celiac Disease current marketed and Celiac Disease emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Celiac Disease Market Dynamics:<\/strong> Celiac Disease market drivers and Celiac Disease market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Celiac Disease Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Celiac Disease Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>To know more about Celiac Disease companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/celiac-disease-cd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Celiac Disease Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify\">1. Celiac Disease Market Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Executive Summary for Celiac Disease<\/p>\n<p style=\"text-align: justify\">3. SWOT analysis of Celiac Disease<\/p>\n<p style=\"text-align: justify\">4. Celiac Disease Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify\">5. Celiac Disease Market Overview at a Glance<\/p>\n<p style=\"text-align: justify\">6. Celiac Disease Disease Background and Overview<\/p>\n<p style=\"text-align: justify\">7. Celiac Disease Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify\">8. Country-Specific Patient Population of Celiac Disease<\/p>\n<p style=\"text-align: justify\">9. Celiac Disease Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify\">10. Celiac Disease Unmet Needs<\/p>\n<p style=\"text-align: justify\">11. Celiac Disease Emerging Therapies<\/p>\n<p style=\"text-align: justify\">12. Celiac Disease Market Outlook<\/p>\n<p style=\"text-align: justify\">13. Country-Wise Celiac Disease Market Analysis (2020&ndash;2034)<\/p>\n<p style=\"text-align: justify\">14. Celiac Disease Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify\">15. Celiac Disease Market Drivers<\/p>\n<p style=\"text-align: justify\">16. Celiac Disease Market Barriers<\/p>\n<p style=\"text-align: justify\">17. Celiac Disease Appendix<\/p>\n<p style=\"text-align: justify\">18. Celiac Disease Report Methodology<\/p>\n<p style=\"text-align: justify\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify\">20. Disclaimer<\/p>\n<p style=\"text-align: justify\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=celiac-disease-market-analysis-2034-industry-trends-market-size-and-emerging-therapeutic-developments-delveinsight-zedira-dr-falk-pharma-takeda-immunogenx-provention-bio-sanofi\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=celiac-disease-market-analysis-2034-industry-trends-market-size-and-emerging-therapeutic-developments-delveinsight-zedira-dr-falk-pharma-takeda-immunogenx-provention-bio-sanofi\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Celiac Disease Companies in the market include &#8211; Takeda, AnokionSA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/619003"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=619003"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/619003\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=619003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=619003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=619003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}